GSK Settles First Zantac Cancer Lawsuit Set for Trial in US
- California man claimed the contaminated drug led to his cancer
- Zantac was found in 2019 to form NDMA, a probable carcinogen
This article is for subscribers only.
GSK Plc reached a settlement with a man who claimed the drugmaker’s blockbuster heartburn medication Zantac caused his cancer, heading off the first such case set to go to trial in the US.
The parties reached a confidential settlement and the case filed in a California state court will be dismissed, GSK said in a statement Friday. The company said it isn’t admitting any liability in the settlement and will continue to defend itself in all other cases related to the drug. Shares of GSK rose as much as 4.8%.